Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.

ABSTRACT:

Background

This study estimated avoided recurrences and treatment costs in patients with stage II-IIIA non-small cell lung cancer treated with adjuvant atezolizumab in five European countries over 10 years (2024-2034).

Materials & methods

Recurrences and deaths were projected in the presence and absence of adjuvant atezolizumab. Inputs were from the literature with extrapolation of disease-free survival from the IMpower010 trial. Country-level direct costs of treating recurrences were estimated.

Results

Adjuvant atezolizumab prevented an estimated 4952 recurrences (2199 locoregional, 2753 metastatic) over 10 years (2024-2034), associated with €264 million savings in treatment costs across the five countries.

Conclusion

Adjuvant atezolizumab may provide a meanin

SUBMITTER: Greystoke A 

PROVIDER: S-EPMC11633414 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature